# Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19

> **NCT06057064** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 116 (actual)

## Conditions studied

- COVID-19, SARS-CoV-2

## Interventions

- **BIOLOGICAL:** Biological: AZD3152
- **BIOLOGICAL:** Biological: Placebo

## Key facts

- **NCT ID:** NCT06057064
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-29
- **Primary completion:** 2024-05-17
- **Final completion:** 2024-05-17
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057064, "Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06057064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*